High-Flow Nasal Oxygen

Alain Mercat
 Conflicts of interests

• Fundings for clinical researchs

• Covidien (PAV+)
• GE (EELV/PEEP/ARDS)
• Maquet (NAVA)
• Fisher-Paykel (Optiflow)
• Patent
• GE (EELV/PEEP/recruitment)
• Fees for lectures
• Covidien
• Fisher Paykel
• Fees for consulting
• Faron Pharmaceuticals
• Air Liquide Medical Systems
 High-Flow Nasal Oxygen

• High flow (up to 60 L/min)

• High FiO2 (upto 100 %)
• Humidification (37 °C, 100 % HR, 44 mg H2O/L)
 HFNO : Potential benefits

Flow O2 ≥ inspiratory flow “CPAP effect”

(stable high FiO2) (recruitment)

Expiratory flushing of
Humidification
CO2 from upper airways
Comfort
(decreased dead space)
 HFNO : Small “CPAP effect”

Nasopharyngeal pressure (cmH2O) [Flow 35 L/min]

NHF NHF FM FM
Mouth Closed Mouth Open Mouth Closed Mouth Open

M 2.7 1.2 0.2 0.1

± ± ± ±
SD 1.0 0.8 0.6 0.4
Parke R, et al. Br J Anaest 2009;103:886-890

30 L/min 40 L/min 50 L/min

Parke R, et al. Respir Care 2011;56:1151-5

Flushing CO2 from upper airway
 Flushing CO2 from upper airway

0 L/min 30 L/min 60 L/min

HFNO : Decreased WOB
 HFNO : Comfort and oxygenation
20 hypoxemic pts (SpO2<96% with FiO2 50%)
Venturi Mask vs HFNO for 30 min

Dyspnea Mouth Dryness Overall Comfort

8 10 10
7
* * *
8 8
6
5 6 6
4
3 4 4
2
2 2
1
0 0 0
FM NHF FM NHF FM NHF

Resp. Rate Gas exchange

30
* 140 *
25 120
100
20
80 PaO2
15
60
10 PaCO2
40
5 20
0 0
FM NHF FM NHF

Roca O, et al. Respir Care 2010;55:408-413

HFNO vs mask O2 : Success rate

60 pts with mild to moderate hypoxemic ARF

High-flow face mask vs NHF for 24 h

Fewer desaturations with NHF (15 vs 26)

Parke R, et al. Respir Care 2011;56:265-70

JP. Frat et al. NEJM 2015
 FLORALI trial

Exclusion criteria:
– PaCO2 > 45 mmHg
– NIV contraindications
– urgent need for intubation
– Exacerbation of chronic
respiratory insufficiency
– cardiogenic pulmonary edema
– shock
– Glasgow coma score <12
– neutropenia (<500/mm3)
 FLORALI trial
Pre-determined criteria for intubation

Glasgow coma score Hemodynamic

<12 instability
Respiratory failure *

≥2 criteria:
– RR >*NIV/HFNC
40/minas rescue was possible
– copious tracheal
in HFNC secretions
and standard O2 groups

– acidosis with pH <7.35

– SpO2 <90% for more than 5 min
– intolerance to NIV
 Characteristics of patients

Oxygen Group HFNC Group NIV/HFNC Group

Characteristics at inclusion
(n=94) (n=106) (n=110)

Age – yr 59±17 61±16 61±17

Male sex – no. (%) 63 (67.0) 75 (70.7) 74 (67.3)
Body-mass index 26±5 25±5 26±6
SAPS II at inclusion 24±9 25±9 27±9
SOFA score at inclusion 3.6±1.8 3.7±2.0 4.2±2.1
Preexisting cardiac failure - no. (%) 4 (4.3) 8 (7.5) 8 (7.3)
Immunodeficiency – no. (%): 30 (31.9) 26 (24.5) 26 (23.6)
Liver cirrhosis – no. (%) 5 (5.3) 6 (5.7) 5 (4.5)
Smoker – no. (%) 36 (38.3) 34 (32.1) 40 (36.4)
Reason for acute respiratory failure, no. (%)
Community-acquired pneumonia 57 (60.6) 71 (67.0) 69 (62.7)
Hospital acquired pneumonia 13 (13.8) 12 (11.3) 12 (10.9)
other 24 (25.5) 23 (21.7) 29 (26.4)
Bilateral pulmonary infiltrates – no. (%) 80 (85.1) 79 (74.5) 85 (77.3)
 Characteristics of patients (2)

Oxygen Group HFNC Group NIV/HFNC group

Characteristics at inclusion
(n=94) (n=106) (n=110)

Clinical parameters

Respiratory rate - breath/min 32±6 33±6 33±7

Heart rate - beats/min 104±16 106±21 106±21

Systolic arterial pressure – mmHg 130±22 127±24 128±21

Mean arterial pressure – mmHg 89±15 87±17 86±16

Arterial blood gas

pH 7.44±0.06 7.43±0.06 7.43±0.06

PaO2 – mmHg 91±33 85±31 90±35

FiO2 0.66±0.12 0.66±0.13 0.64±0.14

PaO2:FiO2 ratio– mmHg 146±53 137±56 150±62

PaCO2 – mmHg 35±5 36±6 34±6

 Respiratory comfort and gas exchange

Oxygen group HFNC group NIV/HFNC group

P Value
(n=74) (n=86) (n=91)

Respiratory patient-discomfort at inclusion – mm 44±29 38±31 46±30 0.20

Respiratory patient-discomfort at H1– mm 40±29 29±26 43±29 <0.01

Grade of dyspnea at H1 <0.001

Marked improvement – no. (%) 5 (6.8) 19 (22.1) 13 (14.3)

Slight improvement– no. (%) 26 (35.1) 46 (53.5) 40 (44.0)

No change– no. (%) 33 (44.6) 18 (20.9) 23 (25.3)

Slight deterioration – no. (%) 9 (12.2) 3 (3.5) 8 (8.8)

Marked deterioration – no. (%) 1 (1.3)) 0 (0.0) 7 (7.7)

Respiratory rate at H1 – cycles/min 31±7 28±7 31±8 <0.01

PaO2 at H1– mm Hg 91±32 106±66 118±72 <0.05

PaO2:FiO2ratio at H1 – mm Hg 146±69 133±73 183±83 <0.001

 Primary outcome: Intubation rate
Oxygen group HFNC group NIV/HFNC group
(n=94) (n=106) (n=110) P Value
Intubation – no. (%) 44 (46.8) 40 (37.7) 55 (50.0) 0.17
Interval between baseline
15 [5-39] 27 [8-46] 27 [8-53] 0.27
and intubation – hours
Cumulative probability of not being intubated

1.0
P=0.17
0.9

0.8

0.7 HFNC group

0.6 Oxygen group

0.5
NIV/HFNC group
0.4

0 2 4 6 8 10 12
Days after Enrollment
 Intubation rate in patients with P/F ≤200 (n=238)

Oxygen group HFNC group NIV/HFNC group

(n=74) (n=83) (n=81) P Value

Intubation – no. (%) 39 (52.7) 29 (34.9) 47 (58.0) <0.01

Cumulative probability of not being intubated

1.0
P=0.009

0.8

HFNC group

0.6
Oxygen group

NIV/HFNC group
0.4

0 2 4 6 8 10 12
Days after Enrollment
 Secondary outcomes:
in-ICU mortality, day 90 mortality, Day 28 VFD

Oxygen group HFNC group NIV/HFNC group

(n=94) (n=106) (n=110) P Value

ICU mortality – no. (%) 18 (19.1) 12 (11.3) 27 (24.5) <0.05

Mortality at day 90– no. (%) 22 (23.4) 13 (12.3) 31 (28.2) <0.05
Ventilator-free days at day 28 – day 22±10 24±8 19±12 <0.05

1.0
Cumulative Probability of Survival

HFNC group
0.9
Oxygen group
0.8

0.7 NIV/HFNC group

0.6

0.5
P=0.015
0.4

0 30 60 90
Days after enrollment
 Reintubation :

- 14 % (HFNO) vs 13 % (NIV)

In ICU mortality :

- 6.8 % % HFNO vs 5.5 % NIV

Stephan et al. JAMA 2015;313:2331-39

Hernandez. JAMA. 2016 Apr 5;315:1354-61
 HFNO in ARF

• Simple and effective method for delivering oxygen therapy

• Better than conventional, low-flow devices in terms of gas

exchange, respiratory rate, and comfort

• Florali trial suggests an improved outcome compared to

conventional O2 therapy and to NIV in hypoxemic ARF

• Studies suggest effectiveness for oxygen therapy after extubation

• Usefulness in other indications (CPE, exacerbation of COPD, …) ?

 Thank you !

[email protected]